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Background: Disturbances of the circadian rhythm of cortisol secretion are associated with depression, coronary
calcification, and higher all-cause and cardiovascular mortality.
The primary aim of this study was to test the associations between midnight salivary cortisol (MSC), depression and
HbA1c, and control for behavioural, environmental and intra individual factors with possible impact on cortisol
secretion, like smoking, physical inactivity, season, medication, diabetes duration, severe hypoglycemia episodes,
age and gender in patients with type 1 diabetes. Secondary aims were to present MSC levels for a reference group
of non-depressed type 1 diabetes patients with a healthy life style (physically active and non-smoking), and to
explore seasonal variations.
Methods: A cross-sectional population based study of 196 patients (54% men and 46% women) aged 18–59 years
that participated in a randomized controlled trial targeting depression in type 1 diabetes. Depression was assessed
by the Hospital Anxiety and Depression Scale-depression subscale. MSC, HbA1c, serum-lipids, blood pressure, waist
circumference and data from medical records and the Swedish National Diabetes Registry were collected.
Results: Thirty four patients (17%) had MSC ≥9.3 nmol/L, which was associated with smoking (AOR 5.5), spring
season (AOR 4.3), physical inactivity (AOR 3.9), self-reported depression (AOR 3.1), and older age (per year) (AOR
1.08). HbA1c >70 mmol/mol (>8.6%) (AOR 4.2) and MSC ≥9.3 nmol/L (AOR 4.4) were independently linked to
self-reported depression. Season was strongly associated with MSC levels and no other variables studied showed
seasonal variations. In a reference group of 137 non-depressed patients with a healthy life style (physically active,
non-smoking) the median MSC level was 4.6 nmol/L (range 1.9–23.0).
Conclusions: In this study of patients with type 1 diabetes high MSC was linked to smoking, physical inactivity,
depression, season and older age. Thus a high cortisol value identified three major targets for treatment in type 1
diabetes.
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Depression is common in persons with diabetes [1,2], af-
fects women twice as often as men [3], and is associated
with impaired glycemic control [1,2,4], diabetes compli-
cations [1,2], and all-cause mortality [5]. Hyperactivity of
the hypothalamic-pituitary-adrenal (HPA) axis is found
in both depression and in type 1 diabetes [2,3,6], though* Correspondence: eva.melin@ltkronoberg.se
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unless otherwise stated.atypical depression is characterized by a down-regulated
HPA axis [3]. In the extreme case of hypercortisolemia as
in Cushing’s disease, 50–80% of the patients are depressed
at the time of diagnosis [7]. Corticosteroids inhibit hippo-
campal serotonin receptors, and hypercortisolemia is
linked to neurodegeneration and decreased hippocampus
size, all important factors in depressive disorders and for
cognitive function [2]. Improved HPA axis function and
reduced cortisol levels are observed in patients with recov-
ery from depression [2,6,8]. Apart from depression and
cognitive impairment [9], hypercortisolemia is linked totd. This is an Open Access article distributed under the terms of the Creative
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dyslipidemia, immunity changes, osteoporosis, arterio-
sclerosis and cardiovascular disease [3,7,10,11]. A disturb-
ance of the circadian rhythm of cortisol, characterized by
a flatter diurnal cortisol slope, is seen in depressed persons
[12]. This type of disturbance is also associated with
coronary calcification [13], and higher all-cause and car-
diovascular mortality [14]. Seasonal variations are ob-
served for cortisol secretion [15-17], depressive symptoms
in seasonal affective disorder (SAD) [17], and in suicide
incidence with a peak in spring in temperate climates [18].
Seasonal changes in depressive symptoms are considered
to be the result of a failure to adapt to the shift in day
length that accompanies seasonal change [19]. Light is the
most important time-marker for entraining the circadian
rhythms in physiology [20], and the hours of daylight in
Sweden vary widely according to season. Higher salivary
cortisol secretion is observed in women and in older per-
sons [21]. Smoking is linked to high salivary cortisol ex-
cretion, high HbA1c and depressive symptoms [4,22,23].
Physical activity reduces depression, augments the benefits
of antidepressant use [24,25], and physical fitness attenu-
ates increased age related cortisol responses to stress [26].
Antidepressants are associated with alterations of the
HPA axis [27]. Salivary cortisol follows the circadian
rhythm with low levels at night and reflects the bioactive
free molecule below plasma cortisol 500 nmol/L [28-33].
Salivary cortisol is increasingly used to assess hypercorti-
solism as sampling is noninvasive, painless and stress free
[8,10,12-15,17,20,22,28-33].
The main hypothesis of this study was that a disturbed
circadian rhythm manifested by high midnight cortisol is
associated with depression and with impaired glycemic
control in patients with type 1 diabetes. The primary aim
of this study was to test the associations between midnight
salivary cortisol (MSC), depression and HbA1c, and con-
trol for behavioural, environmental and intra individual
factors with possible impact on cortisol secretion like
smoking, physical inactivity, season, medication, diabetes
duration, severe hypoglycemia episodes, age and gen-
der in patients with type 1 diabetes. Secondary aims were
to present MSC levels for a reference group of non-
depressed type 1 diabetes patients with a healthy life style
(physically active and non-smoking), and to explore sea-
sonal variations.
Methods
This study presents cross sectional baseline data from the
randomized control trial (RCT) “Psychological variables
and hyperglycemia in diabetes mellitus” (ClinicalTrials.
gov: NCT01714986) which targets psychological symp-
toms in patients with diabetes and inadequate glycemic
control in a population based cohort of patients with type
1 diabetes. A first baseline study showed that depression,obesity and smoking were independently associated with
high HbA1c [4]. Results of the intervention arms “Affect
School with Script Analysis” and “Basic Body Awareness
Therapy” [34,35] will be followed up in 2015 with primary
outcome prevalence of depression and secondary out-
comes HbA1c levels and prevalence of alexithymia and
anxiety.
Participants and procedures
To explore variables associated with high MSC we con-
secutively recruited 196 persons. Patients attended the
only specialist diabetes outpatient clinic in a county with a
population of 125,000 in South Sweden during 2009 [4].
Inclusion criteria were age 18–59 years and type 1 dia-
betes duration for at least 1 year. Exclusion criteria were
pregnancy, severe somatic comorbidities or diabetes com-
plications (cancer, hepatic failure, or end-stage renal dis-
ease), severe mental disorders (psychotic disorder, bipolar
disorder, severe personality disorder, severe substance
abuse, mental retardation, or other severe cognitive defi-
ciencies), systemic corticosteroid treatment, visual impair-
ment to such a degree that reading the questionnaires was
impossible, or inadequate knowledge of Swedish. Two pa-
tients with eczema and psoriasis, both non-smokers, non-
depressed, physically active, and normotensive, had very
high MSC (82 and 72 nmol/L) and were excluded since
topical steroid contamination was suspected.
There were 62 patients who chose not to deliver MSC
samples and 23 who failed to deliver proper samples.
These 85 patients did not differ from the 196 included
patients regarding smoking (p = 0.13), age (p = 0.15),
gender (p = 0.30), use of antidepressants (p = 0.33), mean
HbA1c (p = 0.34), abdominal obesity (p = 0.38), physical
inactivity (p = 0.68), clinical psychiatric diagnosis (p =
0.71), hypertension (p = 0.80), hyperlipidemia (p = 0.80),
diabetes duration (p = 0.89), or self-reported depression
(p >0.99).
The 196 patients underwent self-reported depression
assessment and their MSC, HbA1c, serum-lipids, waist
circumference (WC) and blood pressure were measured.
Data were also collected from the Swedish National
Diabetes Register (S-NDR), and from computerized
medical records from the Departments of Internal Medi-
cine, Ophthalmology, and Psychiatry (only drug pre-
scription data), and from Primary Care clinics.
The study was approved by the Regional Ethical Review
Board of Linköping University (Registration no. M120-07,
T89-08). All patients provided written informed consent.
Midnight salivary cortisol (MSC)
Each patient collected one MSC sample between 23.30
and 00.30 hours, using the Salivette sampling method
(Salivette®, Sarstedt, Nümbrecht, Germany) [8,13,22,29-33].
Patients had a restriction period of 30 minutes prior to
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use snuff, or perform physical exercise [20,31,32], and
avoid brushing their teeth 60 minutes before sampling.
They were instructed to put the swab below the tongue
until wet, store the sample in a refrigerator, and mail it to
the laboratory the next morning. The samples where cen-
trifuged and frozen at −25 centigrades until assayed
at the Department of Clinical Chemistry, Lund University
Hospital, Lund. The Roche Cobas Cortisolassay®, a com-
petitive Electrochemiluminescence immunoassay (ECLIA)
was used on an Elecsys 2010 immunoanalyser system
(Roche Diagnostics, Mannheim, Germany) [29-32].
In a healthy population without diabetes, late night cor-
tisol ranged from 1.4 to 16.7 nmol/L, and the 95th per-
centile was 8.9 nmol/L [30]. Mean MSC (analysed with
Salivary Cortisol ELISA SLV-2930) for persons with
pseudo-Cushing’s syndrome was 7.7 ± 1.0 nmol/l [8]. To
distinguish Cushing’s disease from pseudo-Cushing’s syn-
drome a cut-off value of MSC ≥9.3 nmol/L was suggested
in the same study, corresponding to a sensitivity of 100%
and a specificity of 83% [8]. Therefore MSC ≥9.3 nmol/L
was defined as a high MSC level with clinical significance
in this study.
Season, self-reported depression, clinical psychiatric
diagnoses and life-style
MSC samples were collected between 29/03/2009 and
18/01/2010, which was divided into three periods. The
first period 29/03/2009 until 31/05/2009 was defined as
spring; the second period 01/06/2009 until 31/08/2009
was defined as summer; and the third period 09/01/2009
until 18/01/2010 was defined as autumn/winter.
Self-reported depression was assessed by Hospital Anxiety
and Depression Scale-depression subscale (HADS-D) con-
sisting of 7 statements with 4 response alternatives from 0
to 3, using the recommended ≥8 points as cut off level
[4,9,34,36]. Positive associations between self-reported de-
pression and clinical psychiatric diagnosis with and with-
out use of antidepressants confirmed the validity of the
HADS-D.
Clinical psychiatric diagnoses were established clinic-
ally prior to recruitment, were dichotomized as having
or not having a psychiatric diagnosis, and used mainly
for validation of the HADS-D.
Smokers were defined as patients having smoked any
amount of tobacco during the last year.
Physical inactivity was defined as moderate activities,
such as 30 minutes of walking, less than once a week.
Metabolic variables and hypoglycemia episodes
Venous HbA1c was analysed with high pressure liquid
chromatography, HPLC - variant II, Turbo analyzer (Bio –
Rad®, Hercules, CA, USA) [37]. HbA1c was converted
from Mono-S and dichotomized at the third quartile (q3),which was defined as high HbA1c (Mono-S >7.7%, DCCT >
8.6%, IFCC >70 mmol/mol) [38].
Serum-lipids were analysed with the enzymatic colour
test (Olympus AU®, Tokyo, Japan). Hyperlipidemia was
defined as S-Cholesterol >4.5 mmol/L and/or S-Low
density lipoprotein cholesterol >2.5 mmol/L (according to
the Swedish national guidelines for diabetes management);
or use of lipid lowering drugs independent of lipid blood
levels. HbA1c and lipids were analysed at the department
of Clinical Chemistry, Växjö Central Hospital.
Blood pressure was measured in the sitting position.
Hypertension was defined as systolic blood pressure
>130 mm Hg and/or diastolic blood pressure >80 mm
Hg (according to the Swedish national guidelines for dia-
betes management); or use of antihypertensive drugs in-
dependent of blood pressure levels.
WC was measured between the lowest rib margin and
iliac crest by a nurse. Abdominal obesity was defined as
WC ≥1.02 m. for men, and as WC ≥0.88 m. for women [4].
A severe hypoglycemic episode was defined as needing
help from another person due to hypoglycemia, and episodes
occurring during the last 6 months were registered [4].
Statistical analysis
SPSS® version 18 (IBM, Chicago, Illinois, USA) was used
for statistical analyses. Fisher’s exact test (two-tailed) was
used to analyse differences of prevalence. Continuous vari-
ables, normally distributed, were presented as mean ± SD,
and Student’s t-test was used for analyses of mean differ-
ences. Non-parametric distribution was presented as me-
dian values (quartile (q)1, q3; range), and analyses were
performed with Kruskal-Wallis test or Mann-Whitney U
test. MSC was dichotomized at 9.3 nmol/L [8], and
HbA1c at 70 mmol/mol (8.6%) [4]. Crude odds ratios
(CORs) were calculated. Variables with p ≤0.20 and gen-
der were entered into multiple logistic regression analysis
(Backward: Wald) with MSC ≥9.3 nmol/L as dependent
variable. Life style variables, antidepressants, season, age,
gender, MSC ≥9.3 nmol/L and HbA1c >70 mmol/L
(>8.6%), were entered into multiple logistic regression
analysis with self-reported depression as dependent vari-
able. Confidence intervals (CIs) of 95% were used. P ≤0.05
was considered statistically significant.
Results
In this study of 196 patients with type 1 diabetes, 54%
men and 46% women with mean age 41.3 (range 18–59)
years and mean diabetes duration 21.1 (range 1–55)
years, we analyzed variables associated with high MSC
levels and self-reported depression. Baseline characteristics
and gender differences are presented in Table 1. Twenty
one (11%) patients used continuous subcutaneous insulin
infusion and 175 (89%) used multiple daily insulin injec-
tions. There were 137 (70%) non-depressed (self-reported),








Age (years) 41.3 ± 11.7 42.6 ± 12.0 39.7 ± 11.2 0.0832
Diabetes duration (years) 21.1 ± 12.2 22.3 ± 12.5 19.7 ± 11.8 0.142
High MSC
MSC ≥9.3 nmol/L 34 (17) 17 (16) 17 (19) 0.71
Psychiatric variables
Depression3 20 (10) 12 (11) 8 (9) 0.64
Clinical psychiatric diagnoses 27 (14) 8 (8) 19 (21) 0.007
Life style factors
Smoking4 16 (9) 11 (11) 5 (6) 0.30
Physical inactivity5 19 (10) 10 (10) 9 (11) > 0.99
Metabolic variables and hypoglycemia
HbA1c mmol/mol 62 ± 13 62 ± 10 64 ± 15 0.302
% 7.9 ± 1.1 7.8 ± 1.0 8.0 ± 1.3
HbA1c >70 mmol/mol (>8.6%) 50 (26) 22 (21) 28 (31) 0.10
Abdominal obesity6 29 (15) 8 (8) 21 (24) 0.002
Hypertension 106 (54) 65 (61) 41 (46) 0.031
Hyperlipidemia 167 (85) 96 (91) 71 (79) 0.027
Severe hypoglycemia episodes7 9 (5) 4 (4) 5 (5) 0.74
Medication
Antidepressants 13 (7) 4 (4) 9 (10) 0.092
Antihypertensive medication 60 (31) 38 (36) 22 (24) 0.090
Lipid lowering drugs 93 (47) 53 (50) 40 (44) 0.48
Inhaled steroids 15 (8%) 4 (4) 11 (12) 0.032
Data are means ± SD or n (%). 1Fisher’s exact test unless otherwise indicated. 2Student’s t-test. 3Self-reported. 4Smoking: 10 missing values. 5Physical inactivity:
12 missing values. 6WC: men ≥1.02 m; women ≥0.88 m. 7At least one severe hypoglycemia episode during the last 6 months where they needed help from
another person.
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tients were either depressed, smokers or physically in-
active, or had combinations of these variables; and 14 (7%)
were non-depressed but with missing data regarding life
style factors. Clinical psychiatric diagnoses were estab-
lished in 27 (14%) patients and 13 used antidepressants.
Their clinical diagnoses were depression (n = 16), anxiety
disorder (n = 4), stress related disorder (n = 4), controlled
alcohol addiction (n = 2), or attention deficit hyperactivity
disorder (n = 1).
MSC for all patients included in the study
For all 196 patients median MSC was 5.0 (q1, q3, range:
3.1, 7.5; 1.9–47.0) nmol/L (Table 2). Median MSC levels
were higher for patients that were smokers (p <0.001),
had self-reported depression (p = 0.005), or were physic-
ally inactive (p = 0.050) (Table 2). Median MSC did not
differ between users and non-users of antidepressants in
patients with self-reported depression (p = 0.76), and not
in patients without self-reported depression (p = 0.90)
(Table 2).Median MSC levels (p <0.001) and the prevalence rates
of high MSC (≥9.3 nmol/L) (p = 0.013) were highest in the
spring samples and lowest in the autumn/winter samples
(Table 3). No seasonal clustering was observed for physical
inactivity, smoking, self-reported depression, HbA1c, gen-
der or age (Table 3).
Thirty four patients (17%) had MSC ≥9.3 nmol/L, which
was associated with smoking (AOR 5.5), spring (AOR 4.3),
physical inactivity (AOR 3.9), self-reported depression
(AOR 3.1), and older age (per year) (AOR 1.08) (Table 4).
MSC in non-depressed (self-reported), non-smoking and
physically active patients
Median MSC (q1, q3; range; 5
th percentile; 95th percent-
ile) nmol/L was 4.6 (3.0, 6.8; 1.9–23.0; 2.0; 12.0) for 137
(55% men) non-depressed, non-smoking and physically
active patients with median (range) age 43 (20–59) years.
In these 137 patients MSC ≥9.3 nmol/L was associated
with season, spring (AOR 7.9 (1.6–37.8), p = 0.010),
summer (AOR 1.9 (0.2–14.5), p = 0.54), autumn/winter
(AOR 1) (reference); but not with age (per year) (1.05
Table 2 Midnight salivary cortisol (MSC) by gender, psychiatric factors, lifestyle, obesity, high HbA1c, hypoglycemia,
and medication in 196 patients with type 1 diabetes
Midnight salivary cortisol (nmol/L)
n (%) Median (q1, q3; range) P
1
All participants 196 5.0 (3.1, 7.5; 1.9–47.0)
Gender
Men 106 (54) 4.6 (3.1, 6.8; 1.9–47.0) 0.062
Women 90 (46) 5.6 (3.2, 8.0; 1.9–23.0 )
Psychiatric variables
Depression2 Yes 20 (10) 7.7 (5.0, 13.0; 1.9–31.0) 0.005
No 176 (90) 4.8 (3.0, 7.1; 1.9–47.0)
Depression2 and antidepressants (Sub analysis)
Depression2, using antidepressants 5 (2) 8.7 (3.3; 18.0; 3.0–26.0) 0.76
Depression2, not using antidepressants 15 (8) 6.7 (5.1; 13.0; 1.9–31.0)
No depression2, using antidepressants 8 (4) 4.4 (3.1; 8.6; 2.9–14.0) 0.90
No depression2, not using antidepressants 168 (86) 4.8 (3.0; 7.1; 1.9–47.0)
Clinical psychiatric diagnoses Yes 27 (14) 5.3 (3.7, 9.4; 1.9–26.0) 0.28
No 169 (86) 5.0 (3.0, 7.4; 1.9–47.0)
Life style factors
Smoking Yes 16 (9) 9.0 (6.6, 11.8; 2.3–47.0) <0.001
No 170 (91) 4.8 (3.0, 7.0; 1.9–31.0)
Physical inactivity Yes 19 (10) 6.3 (4.3, 13.0; 1.9–31.0) 0.050
No 165 (90) 4.9 (3.0, 7.2; 1.9–47.0)
Metabolic variables and hypoglycemia episodes
HbA1c >70 mmol/mol (>8.6%) Yes 50 (26) 5.3 (3.7, 7.6; 1.9–31.0) 0.26
No 146 (74) 4.8 (3.0, 7.5; 1.9–47.0)
Abdominal obesity, men3 Yes 8 (8) 3.8 (2.5, 5.4; 1.9–31.0) 0.37
No 96 (92) 4.8 (3.1, 7.2; 1.9–47.0)
Abdominal obesity, women4 Yes 21 (24) 7.1 (5.1, 8.8; 2.9–20) 0.030
No 65 (76) 5.0 (2.9, 7.8; 1.9–23.0)
Severe hypoglycemia episodes5 Yes 9 (5) 5.4 (3.4, 6.5; 2.4–11.0) 0.96
No 186 (95) 5.0 (3.1, 7.6; 1.9–47.0)
Medication
Antidepressants Yes 13 4.4 (3.3, 9.7; 2.9–26.0) 0.53
No 183 5.0 (3.1, 7.4; 1.9–47.0)
Inhaled steroids Yes 15 (8) 5.4 (3.0, 7.6; 2.3–11.0) 0.88
No 181 (92) 5.0 (3.1, 7.5; 1.9–47.0)
1Mann-Whitney U test. 2Self-reported. 3WC: ≥1.02 m. 4WC: ≥0.88 m. 5At least one severe hypoglycemia episode during the last 6 months where they needed help
from another person.
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median MSC (q1, q3; range) nmol/L was (n = 50) 6.6 (4.5,
8.8; 1.9–23.0), in summer (n = 36) 3.5 (2.7, 5.3; 1.9–14.0);
and in autumn/winter (n = 51) 3.5 (2.8, 5.4; 1.9–11.0),
p <0.001. Median age (range) years in spring was 46
(20–59); in summer 39 (20–59); in autumn/winter 44
(22–59), p = 0.022. Median age did not differ be-
tween patients recruited in spring and autumn/winter
(p = 0.67).Associations with self-reported depression
MSC ≥9.3 nmol/L (AOR 4.4), HbA1c >70 mmol/L
(>8.6%) (AOR 4.2) and antidepressants (AOR 4.9) were
independently associated with self-reported depression
(Table 5).
Validation of the HADS-D
The associations (COR (CI), p) were significant between
self-reported depression and “clinical psychiatric diagnosis









MSC nmol/L 6.7 (4.7, 9.3) 4.6 (2.8, 6.8) 3.5 (2.7, 5.5) <0.0015
MSC ≥9.3 nmol/L Yes 20 (25) 9 (18) 5 (8) 0.013
No 59 (75) 41 (82) 62 (92)
Age (years) 45.0 (32.0, 52.0) 40.0 (28.0, 48.2) 44.0 (32.0, 53.0) 0.0905
Physical inactivity6 Yes 9 (12) 7 (15) 3 (5) 0.21
No 66 (88) 41 (85) 58 (95)
Gender Men 39 (49) 32 (64) 35 (49) 0.25
Women 40 (51) 18 (36) 32 (51)
High HbA1c7 Yes 23 (29) 15 (30) 12 (18) 0.21
No 56 (71) 35 (70) 55 (82)
HbA1c mmol/mol 63 (53, 71) 64 (55, 72) 60 (53, 68) 0.325
% 7.9 (7.0, 8.6) 8.0 (7.2, 8.8) 7.7 (7.0, 8.4)
Smoking8 Yes 9 (12) 4 (8) 3 (5) 0.32
No 66 (88) 45 (92) 59 (95)
Depression9 Yes 11 (14) 4 (8) 5 (8) 0.41
No 68 (86) 46 (92) 62 (92)
Data are n (%) or median (q1, q3).
1(29/03/2009–31/05/2009). 2(01/06/2009–31/08/2009). 3(01/09/2009–18/01/2010). 4Fisher’s exact test unless otherwise indicated.
5Kruskal-Wallis test. 6Physical inactivity: 12 missing values. 7HbA1c >70 mmol/mol (>8.6%). 8Smoking: 10 missing values. 9Self-reported.
Table 4 Associations with high midnight salivary cortisol (MSC) for 181 patients with type 1 diabetes
High midnight salivary cortisol (≥9.3 nmol/L)
COR (95% CI) P1 AOR (95% CI) P2
Smoking 5.5 (1.9–16.1) 0.002 5.5 (1.6–18.5) 0.006
Age (per year) 1.06 (1.02–1.10) 0.002 1.08 (1.03–1.13) 0.001
Season
Spring 4.2 (1.5–11.9) 0.007 4.3 (1.4–13.7) 0.013
Summer 2.7 (0.9–8.7) 0.09 3.4 (0.9–13.0) 0.07
Autumn/winter (reference) 1 1
Physical inactivity 3.0 (1.1–8.3) 0.036 3.9 (1.1–13.4) 0.032
Depression 4.9 (1.9–13.1) 0.001 3.1 (1.0–9.2) 0.047
Women 1.2 (0.6–2.6) 0.66 2.2 (0.9–5.2) 0.089
Antidepressants 2.3 (0.7–7.8) 0.20 - 0.76
Inhaled steroids 0.3 (0.04–2.5) 0.28 - -
Diabetes duration 1.01 (0.98–1.04) 0.40 - -
HbA1c mmol/mol (per unit) 1.01 (0.98–1.04) 0.57 - -
% (per unit) 1.10 (0.80–1.51)
Abdominal obesity, men 0.7 (0.1–6.2) 0.76 - -
Abdominal obesity, women 0.9 (0.3–3.3) 0.92 - -
Missing lifestyle variables for 15 persons (smoking and/or physical inactivity). 1Simple logistic regression. 2Multiple logistic regression analysis (Backward: Wald).
Nagelkerke R Square = 0.311.
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Table 5 Associations with self-reported depression for 181 patients with type 1 diabetes
Self-reported depression
COR (95% CI) P1 AOR (95% CI) P2
MSC ≥9.3 nmol/L 4.9 (1.9–13.1) 0.001 4.4 (1.5–13.0) 0.007
HbA1c >70 mmol/L (>8.6%) 4.3 (1.7–11.1) 0.003 4.2 (1.5–11.8) 0.007
Antidepressants 7.0 (2.0–24.1) 0.002 4.9 (1.2–20.8) 0.030
Women 0.8 (0.3–2.0) 0.58 - 0.17
Physical inactivity3 3.6 (1.1–11.3) 0.030 - 0.18
Age (per year) 1.04 (1.0–1.1) 0.060 - 0.29
Season
Spring 2.0 (0.7–6.1) 0.22 - 0.33
Summer 1.1 (0.3–4.2) 0.91 - 0.33
Autumn/winter (reference) 1 1
Smoking3 2.1 (0.5–8.0) 0.29 - 0.68
Clinical psychiatric diagnosis 7.2 (2.6–19.7) <0.001 - -
Missing life style values for 15 persons. 1Simple logistic regression. 2Multiple logistic regression analysis (Backward: Wald). Nagelkerke R Square = 0.23.
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and between self-reported depression and “clinical psychi-
atric diagnosis without use of antidepressants” (5.7
(1.5–21.3), 0.009 (n = 14)), with “no clinical psychiatric
diagnosis/antidepressants” as reference (n = 169).
Discussion
In this population based study of 196 patients with type 1
diabetes, smoking, physical inactivity, depression and age,
were associated with high MSC (≥9.3 nmol/L), whereas
HbA1c was not. High MSC and high HbA1c (>70 mmol/L
(>8.6%)) were independently associated with depression.
A seasonal variation was found with the highest preva-
lence of high MSC levels in spring and the lowest in
autumn/winter. The main links between these variables
are illustrated in Figure 1.
Strengths of our study are first that we systematically
investigated factors that could confound our results such
as use of antidepressants or inhaled steroids, and sea-
sonal changes in cortisol secretion. Secondly, we deter-
mined factors not associated with high MSC, i.e. HbA1c,
antidepressants and diabetes duration. Third, the popu-
lation of patients with type 1 diabetes was large and well
defined. Pregnant women, patients with severe somatic
or psychiatric disorders including substance abuse, and
patients using systemic corticosteroid treatment, were
excluded, all factors that knowingly affect cortisol levels.
Fourth, we thoroughly examined and found that the eli-
gible 85 patients who did not deliver salivary cortisol
samples did not differ from the 196 included patients.
This suggests that our results could be generalized to a
larger population of patients with type 1 diabetes.
Limitations to our study are first that self-reported de-
pression was not confirmed by a diagnostic interview.
Yet, clinical psychiatric diagnoses, both for those usingand not using antidepressants, were clearly associated
with self-reported depression. Secondly, HbA1c and MSC
were only measured once, but a demand for repeated
measurements would probably have resulted in a lower
participation rate due to the inconvenience with both ven-
ous and midnight sampling. Third, there was no data from
the middle of January until the end of March which makes
it impossible to exclude seasonality in depressive symp-
toms, though we did not find any. Fourth, to confirm the
seasonality of MSC levels there is a need for repeated
measurements throughout the year.
A normal circadian rhythm of cortisol is character-
ized by maximum levels in the morning and mini-
mum levels at midnight [8]. In this study we chose to use
MSC ≥9.3 nmol/L as cut-off, a very high level that was re-
cently used to differentiate pseudo-Cushing’s syndrome
from true Cushing’s disease [8]. The association between
this very high level of midnight cortisol and self-reported
depression indicates a disturbance of the circadian rhythm
in depressed patients with type 1 diabetes. Depression has
previously been linked to hyperactivity of the HPA axis
[2,3], a disturbance of the circadian rhythm characterized
by a flatter diurnal slope of cortisol secretion [12], a down
regulated HPA axis in atypical depression [3], and seasonal
variations with an attenuated cortisol awakening response
in SAD during winter months [17].
We found the highest midnight cortisol levels in spring
and the lowest in autumn/winter which is a new finding.
First, we have not found any previous study where sea-
sonal variations of midnight salivary cortisol were ana-
lysed; measurements have been performed during daytime
and late evening. Second, according to a review of cir-
cannual hormonal changes, basal levels of circulating glu-
cocorticoids seem to be lower during the spring and
summer and peak during the autumn and winter [16].
High cortisol 
(MSC 9.3 nmol/L)






Figure 1 Links with high MSC (≥9.3 nmol/L) and depression. Depression, smoking, physical inactivity, age and season (spring) were linked to
high MSC. High HbA1c and high MSC were independently linked to depression. The arrows are drawn bidirectional between all variables where
bidirectional links can’t be excluded: between depression and high HbA1c, between depression and high MSC, and finally between physical
inactivity and high MSC.
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concentrations at daytime in February, March, and April,
(the high levels in March and April are findings quite con-
sistent with ours), and the lowest concentrations in July
and August (which differ from our findings) [15]. Another
research group found that the cortisol awakening response
was attenuated in persons with SAD during winter
months but did not find any seasonal variations of cortisol
secretion in healthy individuals [17]. Spring is in Sweden
characterized by rapidly increasing light intensity and lon-
ger day light periods, which might influence cortisol secre-
tion as light is an important time-marker for cortisol
secretion [20]. The seasonality in MSC secretion was not
explained by seasonal differences in self-reported depres-
sion, smoking or physical inactivity, or by uneven distribu-
tion of women/men or older/younger during the different
seasons. Actually the association between high MSC and
spring was very high (AOR 7.9) compared to autumn/win-
ter in the non-depressed population with a healthy life
style. Our results suggest that seasonal variations of MSC
should be considered both when MSC is measured for
clinical purposes, and in future research.
Hypercortisolemia is a known cause of hyperglycemia
[7], but we found no direct association between MSC
and HbA1c. The reason could be that the influence of
hypercortisolemia on glycemic control was successfully
counteracted by higher insulin doses; unfortunately we
have no information of their insulin doses. Instead we
found that depression was independently associated both
with high MSC and with high HbA1c.The absence of associations between depression and
gender, physical inactivity and smoking differ from pre-
vious research [3,23,24]. Findings in our study of the
links between high cortisol and smoking and older age
are consistent with previous studies of people without
diabetes [22,26].
We chose a 30 minutes (60 minutes for brushing the
teeth) restriction period of eating etc. before MSC sam-
pling. A variety of restriction periods before salivary cor-
tisol sampling are found in the literature: 15 minutes
[14,22], 30 minutes [20,31,32], 2 hours [8], and 3 hours
[28]. How much a shorter or longer restriction period
would affect the results is difficult to say, but a long re-
striction period might negatively affect the participation
rate, and for patients with type 1 diabetes it is preferable
not to interfere with ordinary mealtimes in order to
avoid hypoglycemia episodes.
The ECLIA method used to analyze MSC in our study is
well validated [29-32], but there are no established refer-
ence ranges for patients with type 1 diabetes. To aid future
research and clinical assessments, reference MSC values
were calculated for non-depressed, non-smoking physically
active patients with type 1 diabetes, and reference ranges
were also presented for the different seasons.
Salivary cortisol will probably be used more in future
clinical practice and research as it can be sampled at
home, is noninvasive, painless and stress free [29,32].
High levels of MSC particularly in younger non-smoking
patients could indicate depression. Normalized cortisol
levels have been observed after resolution of depressive
Melin et al. BMC Endocrine Disorders 2014, 14:75 Page 9 of 10
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toms will lead to decreased MSC levels in patients with
type 1 diabetes is a subject for future research. Other sub-
jects for future research are to explore and compare the
effects on the HPA axis of the different subtypes of antide-
pressants, and to explore the effects of psycho education
and stress reducing techniques on depression and cortisol
secretion in patients with type 1 diabetes [34,35].
Conclusions
High levels of MSC linked to depression, smoking and
physical inactivity highlights three main targets in diabetes
care, as a disturbance of the circadian rhythm of cortisol is
associated with coronary calcification, all-cause and car-
diovascular mortality [13,14].
The additional link between depression and high HbA1c
emphasizes the severity of depression in patients with type
1 diabetes. Routine systematic depression evaluation at
diabetes control visits is suggested. A high cortisol level
may help to emphasize to medical professionals and pa-
tients alike the necessity of taking action against depres-
sion, smoking and physical inactivity.
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